Want to see SLGL full AI Analyst Report?
Top Page
Sol-Gel Technologies
(NASDAQ:SLGL)
Select Model
Select Model
Rating:59Neutral
Price Target:
$81.00
▼(-1.17% Downside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by mixed financial performance—clear 2025 improvement and low debt, but still persistent losses and an eroding equity cushion. Technicals add support with strong price trend and positive momentum indicators, while valuation remains a drag due to the negative P/E and no dividend yield provided.
Positive Factors
Cash runway and funding
The substantial cash balance and stated runway reduce near-term financing pressure, allowing Sol-Gel to complete its pivotal trial and advance commercialization without immediately relying on additional capital.
Negative Factors
High revenue volatility and ongoing losses
The sharp revenue decline shows that reported performance remains vulnerable to nonrecurring items and limited product scale. Continued net losses indicate that commercial revenue has not yet established a dependable earnings base.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash runway and funding
The substantial cash balance and stated runway reduce near-term financing pressure, allowing Sol-Gel to complete its pivotal trial and advance commercialization without immediately relying on additional capital.
Read all positive factors
Sol-Gel Technologies (SLGL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$252.99M
Dividend YieldN/A
Average Volume (3M)34.17K
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue Growth-92.50%
EPS Growth-361.11%
CountryUS
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.54
Shares Outstanding3,268,991
10 Day Avg. Volume44,977
30 Day Avg. Volume34,168
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)5.15
Price to Sales (P/S)6.06
P/FCF Ratio426.90
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$196.67Price Target Upside139.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-8.32
Revenue Forecast (FY)$352.00K
Sol-Gel Technologies Business Overview & Revenue Model
Company Description
Sol-Gel Technologies Ltd., a pharmaceutical firm currently in its clinical development phase, specializes in the creation and market introduction of skin-applied medications. These products leverage the company's distinctive microencapsulation tec...
How the Company Makes Money
Sol-Gel makes money primarily from commercial sales of its dermatology products and from collaboration-related income tied to partnered commercialization. Revenue is generated through: (1) Product sales: income from selling its marketed prescripti...
Sol-Gel Technologies Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.56M | 19.39M | 11.54M | 1.55M | 3.88M | 31.27M |
| Gross Profit | -10.07M | 19.39M | 11.54M | 1.55M | -8.80M | 10.89M |
| EBITDA | -16.43M | -7.43M | -11.78M | -28.96M | -15.68M | 3.84M |
| Net Income | -14.91M | -6.13M | -10.58M | -27.24M | -14.92M | 3.22M |
Balance Sheet | ||||||
| Total Assets | 42.01M | 29.92M | 35.85M | 45.29M | 46.63M | 69.19M |
| Cash, Cash Equivalents and Short-Term Investments | 30.47M | 24.00M | 23.93M | 38.00M | 33.63M | 43.24M |
| Total Debt | 1.39M | 991.00K | 1.31M | 1.65M | 772.00K | 1.59M |
| Total Liabilities | 7.10M | 7.11M | 7.00M | 6.64M | 4.42M | 13.60M |
| Stockholders Equity | 34.90M | 22.81M | 28.85M | 38.64M | 42.21M | 55.59M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 275.00K | -13.89M | -17.86M | -9.65M | -7.83M |
| Operating Cash Flow | 0.00 | 322.00K | -13.89M | -17.73M | -9.48M | -7.69M |
| Investing Cash Flow | 0.00 | -8.58M | 26.69M | -9.74M | 1.70M | 19.87M |
| Financing Cash Flow | 0.00 | 6.00K | 0.00 | 21.81M | 15.00K | 837.00K |
Sol-Gel Technologies Risk Analysis
Sol-Gel Technologies disclosed 72 risk factors in its most recent earnings report. Sol-Gel Technologies reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sol-Gel Technologies Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $252.99M | -13.72 | -44.05% | ― | -92.50% | -361.11% | |
56 Neutral | $792.87M | -15.49 | -43.57% | ― | -66.63% | 57.89% | |
53 Neutral | $550.74M | -7.92 | -23.64% | ― | -76.20% | 52.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $141.37M | -2.84 | 271.76% | ― | -60.77% | 57.26% | |
45 Neutral | $281.73M | -0.57 | 187.62% | ― | -8.79% | -195.46% | |
40 Underperform | $45.71M | -0.49 | -63.65% | ― | -59.84% | -5.97% |
* Healthcare Sector Average
SLGL
Sol-Gel Technologies
79.43
57.48
261.87%
IMDX
Insight Molecular Diagnostics
4.30
1.82
73.39%
OVID
Ovid Therapeutics
2.88
1.62
128.57%
STTK
Shattuck Labs
8.06
7.06
706.00%
SRZN
Surrozen
23.36
11.96
104.91%
MGX
Metagenomi, Inc.
1.21
-0.65
-34.95%
Sol-Gel Technologies Corporate Events
Sol-Gel Technologies Posts Q2 Loss as Pivotal Gorlin Syndrome Trial Advances Toward Late-2026 Readout
Aug 20, 2026
On August 20, 2026, Sol-Gel Technologies reported its second-quarter results for the period ended June 30, 2026, highlighting steady execution across its clinical programs despite a sharp year-on-year revenue decline. The company posted revenue of...
Sol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million Offering
May 28, 2026
In the first quarter of 2026, Sol-Gel Technologies secured a U.S. Notice of Allowance for a key method-of-use patent on topical patidegib (SGT-610), extending intellectual property protection until 2044 and strengthening the long-term value of its...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.